Skip to main content
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1999;7(4):186–189. doi: 10.1002/(SICI)1098-0997(1999)7:4<186::AID-IDOG4>3.0.CO;2-Z

A randomized, double-blind, placebo-controlled trial of 5-fluorouracil for the treatment of cervicovaginal human papillomavirus.

M M Holmes 1, S H Weaver 2nd 1, S T Vermillion 1
PMCID: PMC1784744  PMID: 10449266

Abstract

OBJECTIVE: To compare intravaginal 5-fluorouracil (5-FU) and placebo for the treatment of cervical and/or vaginal human papillomavirus (HPV). METHODS: A randomized, placebo-controlled trial was performed. Women with HPV detected visually or by Papanicolaou (Pap) test and confirmed by colposcopic biopsy were randomized to receive either intravaginal 5-FU cream or an intravaginal placebo cream. Women with cervical or vaginal intraepithelial neoplasia were excluded. The primary outcome measure was cytologic regression of HPV as determined by Pap test screening 4 to 6 months after treatment. The secondary outcome was cytologic evidence of disease progression at both the 4-6-month and 12-month follow-up evaluations. Data were analyzed using the Chi square test with significance established at P < 0.05. RESULTS: A total of forty patients were randomized, and thirty patients had a follow-up Pap test 4 to 6 months after treatment. Of those patients treated with 5-FU, 28% demonstrated regression of HPV on cytologic evaluation, compared with 69% of those treated with placebo (P < 0.05). Twelve-month follow-up cytology was available from 18 of the study participants. There were no significant differences in the frequency of cytologic progression or regression between groups at 12 months. CONCLUSION: Four to six months post treatment, the use of intravaginal 5-FU for the treatment of cervical or vaginal HPV is associated with a lower rate of regression than the use of placebo.

Full Text

The Full Text of this article is available as a PDF (307.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellina J. H. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol. 1983 Oct 15;147(4):375–378. doi: 10.1016/s0002-9378(16)32228-1. [DOI] [PubMed] [Google Scholar]
  2. Brodman M., Dottino P., Friedman F., Jr, Heller D., Bleiweiss I., Sperling R. Human papillomavirus-associated lesions of the vagina and cervix. Treatment with a laser and topical 5-fluorouracil. J Reprod Med. 1992 May;37(5):453–456. [PubMed] [Google Scholar]
  3. Brown M. S., Phillips G. L., Jr Management of the mildly abnormal Pap smear: a conservative approach. Gynecol Oncol. 1985 Oct;22(2):149–153. doi: 10.1016/0090-8258(85)90020-4. [DOI] [PubMed] [Google Scholar]
  4. Carmichael J. A., Maskens P. D. Cervical dysplasia and human papillomavirus. Am J Obstet Gynecol. 1989 Apr;160(4):916–918. doi: 10.1016/0002-9378(89)90310-4. [DOI] [PubMed] [Google Scholar]
  5. Dungar C. F., Wilkinson E. J. Vaginal columnar cell metaplasia. An acquired adenosis associated with topical 5-fluorouracil therapy. J Reprod Med. 1995 May;40(5):361–366. [PubMed] [Google Scholar]
  6. Ferenczy A. Comparison of 5-fluorouracil and CO2 laser for treatment of vaginal condylomata. Obstet Gynecol. 1984 Dec;64(6):773–778. [PubMed] [Google Scholar]
  7. Husseinzadeh N., Guoth J. G., Jayawardena D. S. Subclinical cervicovaginal human papillomavirus infections associated with cervical condylomata and dysplasia. Treatment outcomes. J Reprod Med. 1994 Oct;39(10):777–780. [PubMed] [Google Scholar]
  8. Krebs H. B., Helmkamp B. F. Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions. Obstet Gynecol. 1991 Aug;78(2):205–208. [PubMed] [Google Scholar]
  9. Krebs H. B. Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina. Obstet Gynecol. 1986 Dec;68(6):837–841. [PubMed] [Google Scholar]
  10. Krebs H. B. Treatment of vaginal condylomata acuminata by weekly topical application of 5-fluorouracil. Obstet Gynecol. 1987 Jul;70(1):68–71. [PubMed] [Google Scholar]
  11. Malviya V. K., Deppe G., Pluszczynski R., Boike G. Trichloroacetic acid in the treatment of human papillomavirus infection of the cervix without associated dysplasia. Obstet Gynecol. 1987 Jul;70(1):72–74. [PubMed] [Google Scholar]
  12. Richart R. M. Causes and management of cervical intraepithelial neoplasia. Cancer. 1987 Oct 15;60(8 Suppl):1951–1959. doi: 10.1002/1097-0142(19901015)60:8+<1951::aid-cncr2820601505>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  13. Syrjänen K., Väyrynen M., Saarikoski S., Mäntyjärvi R., Parkkinen S., Hippeläinen M., Castren O. Natural history of cervical human papillomavirus (HPV) infections based on prospective follow-up. Br J Obstet Gynaecol. 1985 Nov;92(11):1086–1092. [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES